<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200506047319N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-22</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of thyme on corona patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the therapeutic effect of thyme essence in corona patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-05-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48095</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Assign patients to two groups of intervention and control using the table of online random numbers (kit set).</study_design>
      <phase>N/A</phase>
      <hc_freetext>New Corona virus infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to receiving medication based on hospital protocol, patients receive 15 cc of daily syrup containing 10% thyme essence  in three divided doses. The syrup was prepared by Gol Daru Company on the order of the University of Medical Sciences. Intervention 2: Control group: The only treatment based on hospital protocol is similar to the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be summarized in the form of tables and diagrams in the form of an article

When:
At the end of the study, access will begin at most 6 months after the article is published.

To whom:
The documents will be provided to researchers working at Zanjan University of Medical Sciences and research committees as needed.

Conditions:
Documents will only be available for limited research.

Where to obtain:
To the Vice Chancellor for Research and Technology of Zanjan University of Medical Sciences

How to obtain:
Considering that he is the material and spiritual owner of Zanjan University of Medical Sciences. Written consent must be obtained from the University of Medical Sciences and the Vice Chancellor for Research and Technology.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Narjes Khavasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vice Chancellor for Research and Technology, Third floor, Second building, Zanjan University of Medical Sciences, Azadi Blvd.</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515613191</zip>
        <telephone>+98 24 3315 6393</telephone>
        <email>nxavasi@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Narjes Khavasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vice Chancellor for Research and Technology, Third floor, Second building, Zanjan University of Medical Sciences, Azadi Blvd.</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515613191</zip>
        <telephone>+98 24 3315 6393</telephone>
        <email>nxavasi@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People infected by new corona virus
Age over 18 years and under 50 years
Patients with covid virus 19 hospitalized in Valiasr Hospital</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Respiratory diseases
Pregnant woman
Allergic diseases
Dissatisfaction with participating in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J00-J99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>بیماری‌های دستگاه تنفسی</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to receiving medication based on hospital protocol, patients receive 15 cc of daily syrup containing 10% thyme essence  in three divided doses. The syrup was prepared by Gol Daru Company on the order of the University of Medical Sciences.</i_keyword>
      <i_keyword>Control group: The only treatment based on hospital protocol is similar to the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cough. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fever. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Runny nose. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Shortness of breath. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Headache. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Muscle pain. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Sore throat. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Anorexia. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Weakness and lethargy. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Percentage of people who are tired. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Multi-Dimensional Fatigue Questionnaire of Asmets (MFI).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-04-29</approval_date>
        <contact_name>Zanjan University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, Zanjan University of Medical Sciences,Third floor, second building, Azadi Blvd. Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
